Intech Investment Management LLC Makes New $620,000 Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Intech Investment Management LLC bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,593 shares of the company's stock, valued at approximately $620,000.

Several other large investors have also modified their holdings of the business. Tidal Investments LLC increased its position in shares of Prestige Consumer Healthcare by 4.7% during the first quarter. Tidal Investments LLC now owns 5,748 shares of the company's stock valued at $417,000 after acquiring an additional 256 shares during the last quarter. Atria Investments Inc purchased a new stake in Prestige Consumer Healthcare in the first quarter valued at approximately $1,246,000. EverSource Wealth Advisors LLC lifted its stake in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after purchasing an additional 208 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Prestige Consumer Healthcare by 51.3% during the second quarter. GAMMA Investing LLC now owns 776 shares of the company's stock worth $53,000 after buying an additional 263 shares during the period. Finally, Trust Co. of Vermont grew its stake in shares of Prestige Consumer Healthcare by 18.5% in the second quarter. Trust Co. of Vermont now owns 11,022 shares of the company's stock valued at $759,000 after buying an additional 1,721 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Insiders Place Their Bets

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company's stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. This represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Stock Up 0.7 %

NYSE PBH traded up $0.60 during trading hours on Friday, hitting $84.77. 164,911 shares of the company were exchanged, compared to its average volume of 302,709. Prestige Consumer Healthcare Inc. has a 52-week low of $56.61 and a 52-week high of $86.36. The company has a 50 day moving average of $75.41 and a two-hundred day moving average of $71.16. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of 20.63, a PEG ratio of 2.38 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analysts' expectations of $282.09 million. During the same period in the prior year, the firm posted $1.07 EPS. The business's quarterly revenue was down .9% compared to the same quarter last year. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on PBH. DA Davidson restated a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reissued a "hold" rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $83.67.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.